Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus albumin-bound paclitaxel/cisplatin for recurrent or metastatic cervical cancer (Phase II, single-arm)
ChiCTR2000037497Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in Cervical Cancer (CC), sponsored by Shandong Cancer Hospital. Primary endpoints: Progression-free survival (PFS) and Objective response rate (ORR). Planned start Sep 2020; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2000037497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037497.